Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:REV-ERB_agonist
gptkb:synthetic_compound |
| gptkbp:administeredBy |
mice
|
| gptkbp:CASNumber |
1379686-29-9
|
| gptkbp:chemicalClass |
benzoxazepine derivative
|
| gptkbp:compatibleWith |
human use
|
| gptkbp:developedBy |
gptkb:Scripps_Research_Institute
|
| gptkbp:effect |
reduced fat mass
improved exercise capacity increased energy expenditure |
| gptkbp:mechanismOfAction |
REV-ERB nuclear receptor agonism
|
| gptkbp:modulatedBy |
metabolism
circadian rhythm |
| gptkbp:relatedTo |
SR9009
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:studiedBy |
obesity
inflammation metabolic disorders |
| gptkbp:target |
gptkb:REV-ERBα
gptkb:REV-ERBβ |
| gptkbp:bfsParent |
gptkb:SR_90001
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
REV-ERB agonist SR9001
|